Yang Yin Fu Zheng Jie Du Therapy in Recurrence of Hepatocellular Carcinoma Less Than 3 cm in Diameter

• Status: Completed
• Trial end date: 2021-02-28
• Target enrollment: 0
• Participant gender: All

Summary

Clinical research of Yang Yin Fu Zheng Jie Du therapy in recurrence of Hepatocellular Carcinoma less than 3 cm in diameter.The purpose of this study is to observe the efficacy of routine medical care combined with Yang Yin Fu Zheng Jie Du therapy in 1 year recurrence for patients belong to Hepatocellular Carcinoma less than 3 cm in diameter.

• Phase: Early Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Beijing Ditan Hospital
• Collaborator: Xiyuan Hospital of China Academy of Chinese Medical Sciences

Criteria

Inclusion Criteria:

• Meet the criteria of hepatocellular carcinoma

• Ages Eligible for Study: ≤75 years old;

• The size of the main nodule and multi-centricity (single lesion, three nodules ≤3 cm)

• After transarterial chemoembolisation (TACE) or radiofrequency ablation (RFA)

• Surgery cannot be allowed;

• Informed consent from the patient.

Exclusion Criteria:

• Serious problem of heart, lung, or kidney with severe dysfunction;

• Pregnant or child breast feeding women;

• Mental or cognitive disorders;

• Participating in other drug trials;

• Who are allergic to the study drug.